Ipsen, Inspiration Pharmaceuticals to develop hemophilia franchise
PARIS Despite its rarity, occurring in 1-in-5,000 to 1-in-25,000 male births, hemophilia can be a debilitating condition for patients, with about 60% having severe forms of the condition. But two companies will collaborate to develop treatments for the disease.
Ipsen and Inspiration Pharmaceuticals announced Thursday that they would work together to create a hemophilia franchise whose sales could exceed $1 billion by 2020. Ipsen will acquire an initial 20% stake in Inspiration for $85 million, with the potential to acquire an additional 27% through additional milestone payments of up to $174 million.
The deal includes an in-licensing of Ipsen’s investigational drug OBI-1 and Inspiration’s IB1001, both recombinant protein drugs that will enter phase 3 clinical trials this year. Ipsen will sublicense OBI-1 to Inspiration for $50 million in convertible notes and a 27.5% royalty on future sales of the drug while providing up to $259 million in funding to the company.
“Inspiration has both a strong development experience and a broad pipeline that will provide the opportunity for new growth on our way to building a new, multi-product global franchise for Ipsen in hematology,” Ipsen chairman and CEO Jean-Luc Belingard said in a statement. “We are impressed by the track record of Inspiration’s management team in this field.”
Profession is in ‘revolutionary’ times, says NACDS’ top pharmacy official
NEEDHAM, Mass. Pharmacy practitioners need to recognize that the profession is now in the midst of “revolutionary” changes and adapt to a far more proactive role in patient outreach and community care, a top executive with the National Association of Chain Drug Stores told more than 300 leaders in health care, business, government and community activism here Tuesday.
As the health paradigm shifts, pharmacists need to leverage their strengths as “medication experts” who can coordinate healthcare efforts within the community, and put patients at the center of those efforts, said Edith Rosato, SVP pharmacy affairs for NACDS and president of the NACDS Foundation. Rosato was addressing a meeting of the Massachusetts Health Council, the nation’s the largest and oldest council devoted to health issues.
The subject of her talk: “Transforming Pharmacy Practice: Managing a Changing Environment.” In her address, Rosato tracked community pharmacy’s evolving role and its ability, as a profession, to adapt to changes in the U.S. healthcare system.
“Pharmacy is embarking on revolutionary times,” Rosato asserted. ”It is only fitting that in the nation’s birthplace — Massachusetts — I lay out the importance of revolutionary change in our field. Only by recognizing this change can we learn to adapt our protocols and practices to better position pharmacy in medication adherence activities, which [improving] health outcomes for patients while also reducing overall healthcare expenditures.
“As the face of neighborhood health care, it is not only our duty to transform to better serve our patients — it is our responsibility,” she added.
By utilizing the accessibility and credibility of pharmacy with the effective use of health information technology and management efficiencies, Rosato told members of the council, pharmacists could play an even bigger role in proactive and integrated patient-centric health care. Among the tools they already wield, she said, are medication therapy management services, vaccinations, patient counseling, and prevention-and-wellness programs.
In a bit of irony, Rosato’s appearance in Massachusetts came as voters in this state were dealing the Obama administration a serious setback in its health-reform efforts by electing Republican Scott Brown to succeed Edward Kennedy, one of the Senate’s most vocal champions of health reform before his death last year.
Brown has vowed to fight reform legislation as the 41st Republican senator, and his election breaks the filibuster-proof, 60-vote majority Democrats have held in the Senate.
JDRF, Axxam, Fast Forward to develop diabetes, MS treatments
NEW YORK A group of companies and organizations plan to collaborate to develop new treatments for multiple sclerosis and Type 1 diabetes.
Italian life sciences company Axxam, the Juvenile Diabetes Research Foundation and Fast Forward, the commercial drug development arm of the National Multiple Sclerosis Society, will fund the discovery of new drugs for the two autoimmune diseases.
Axxam will screen its chemical library to identify compounds that can target immune system ion channels, pores in the surface of immune cells that allow the cells to activate. Recent research has shown that the immune cells of patients with MS and Type 1 diabetes have high levels of the Kv1.3 ion channel, and the resulting hyperactivity contributes to dysfunction of the immune system. Meanwhile, the JDRF and Fast Forward will seek to lessen the risk of drug discovery and accelerate the development of new therapies.
“We are pleased to partner with Axxam and JDRF to advance the development of new treatments for [Type 1 diabetes] and MS,” Fast Forward president Timothy Coetzee said.